

CMS Reminds Physicians of HIPAA X12 Deadline

BY MARY ELLEN SCHNEIDER

Physicians have a little more than 2 years to complete their transition to new HIPAA X12 standards for submitting administrative transactions electronically, according to Medicare officials.

As of Jan. 1, 2012, physicians and all other entities covered under HIPAA (Health Insurance Portability and Ac-

countability Act) will be required to use the HIPAA X12 version 5010 format when submitting claims, receiving remittances, and sending claim status or eligibility inquiries electronically. The new standard replaces the version 4010A1 currently in use. The change will affect dealings not only with Medicare, but also with all private payers.

The Medicare fee-for-service program will begin its own system testing next

year and will begin accepting administrative transactions using the 5010 version as of Jan. 1, 2011. Throughout 2011, the Centers for Medicare and Medicaid Services will accept both the 5010 and 4010A1 versions. However, beginning on Jan. 1, 2012, only transactions submitted using the 5010 version will be accepted.

During a recent conference call to update providers, officials at the Centers

for Medicare and Medicaid Services urged physicians not to wait until the last minute to make the transition to the new format.

"There's no room to delay. We cannot possibly convert all of the Medicare trading partners at the 11th hour," said Christine Stahlecker, who is director of the division of Medicare billing procedures in the CMS Office of Information Services.

The switch is necessary, according to the CMS, because the 4010A1 version is outdated. For example, the industry currently relies heavily on companion guides to implement the standards, which limits their value. The new version includes some new functions aimed at improving claims processing, such as resolving ambiguities in the situational rules and providing more consistency across transactions.

But Medicare officials urged physicians to analyze the new version carefully prior to implementation. Billing software will need to be updated, and business processes may need to be changed as well. "There are real changes in these formats," Ms. Stahlecker said.

A comparison of the current and new formats can be viewed online at www.cms.hhs.gov/ElectronicBillingEDITrans/18_5010D0.asp.

INDEX OF ADVERTISERS

Almond Board of California	
Almonds	18
Amylin Pharmaceuticals, Inc.	
Byetta	33-34
Cephalon, Inc.	
Amrix	5-6
Comcast	
Corporate	61
Daiichi Sankyo, Inc.	
Welchol	16a-16b
Eisai Inc. and Pfizer Inc.	
Aricept	26a-26b
Endo Pharmaceuticals	
Lidoderm	58-60
Forest Laboratories, Inc.	
Namenda	8a-8b
Bystolic	11-14
Lexapro	19-23
Savella	45-49
Eli Lilly and Company	
Evista	28-31
Humalog	63-64
Merck & Co., Inc.	
Janumet	42a-42b, 43
Varivax	56a-56b
Novo Nordisk Inc.	
Levemir	15-16
Pfizer Inc.	
Lipitor	3-4
Helpful Answers	7
Toviaz	37-40
PriCara	
NUCYNTA	34a-34d, 35
Sanofi Pasteur Inc.	
Adacel	25-26
Schering-Plough HealthCare Products, Inc.	
Claritin Eye	55
Takeda Pharmaceuticals North America, Inc.	
Uloric	51-52
VISA	
Corporate	41
Wyeth Pharmaceuticals Inc.	
Pristiq	67-68

Early-bird
Discounts
Available

Treat your patient. Treat yourself.

Register Now for the Fifth Annual Chicago Supportive Oncology Conference

Gain important insight about practical management issues in palliative and supportive care. Learn to:

- Identify and treat depression and other psychiatric conditions in the patient with cancer
- Identify cancer survivors at risk for anorexia, cachexia, and other nutritional deficits and incorporate a nutritional plan into their overall care plan
- Recognize neurotoxicities associated with cancer treatments and strategies for management
- Describe and address issues in cancer pain management, including management of addictive disease and hyperalgesia and opioid-induced pain
- Summarize the role of complementary therapies in supportive cancer care, particularly acupuncture and mind-body interventions
- Explain the effects of cancer treatments on sexuality and fertility and the current approaches for their management
- Provide mentorship for colleagues in integrating supportive and palliative care into daily clinical practice
- Identify effective strategies to improve communication issues surrounding the cancer diagnosis, including prognosis, talking with children, and cultural sensitivity
- Describe palliative measures in advanced disease, specifically lung cancer and liver metastases
- Integrate evidence-based management of cancer-related mucositis, refractory nausea and vomiting, and diarrhea into a patient's plan of care
- Evaluate current clinical data on growth factor support, cardiovascular complications with VEGF inhibitors, and skin complications of targeted therapies

Fifth Annual Chicago Supportive Oncology conference

October 1-3, 2009
Hotel InterContinental
Chicago, Illinois

DISCUSSION TOPICS:

- Psycho-oncology
- Nutrition and cancer
- Neurotoxicities
- Cancer-related pain
- Complementary and alternative medicines
- Sexuality and fertility
- International issues
- Communication skills
- Palliation of advanced disease
- Symptom management
- Growth factor pros and cons

15.25 CME credits
14.9 CNE credits
15.3 CPE credits

Register at:
www.supportiveoncology.net/chicago

Jointly sponsored by: **ONCOLOGY** **MENIUS** Educational Institute

Also presented by: **ONCOLOGY** **OncologySTAT**

ASCO
Recognized by ASCOP
Not an ASCO sponsored event

Fifth Annual Chicago Supportive Oncology conference

Register now and **SAVE**

www.supportiveoncology.net/chicago